Crestone presents a poster at New Antibacterial Discovery and Development Gordon Research Conference, Ventura Beach, CA: CRS3123, a novel drug candidate for the treatment of Clostridium difficile infection, is safe, well-tolerated and exhibits high intestinal levels with minimal disruption of normal flora in healthy volunteers in two Phase 1 studies
